tokens: A pooled analysis of randomized , controlled studies of meloxicam therapy of up to 60 days duration found that meloxicam was associated with a statistically significantly lower number of thromboembolic complications than the NSAID diclofenac ( 0.2 % versus 0.8 % respectively ) but a similar incidence of thromboembolic events to naproxen and piroxicam .